ArticleBritish journal of cancer2013
Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 68 citations in OpenAlex.
- Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.The Lancet. Oncology · 2015Trial
- Prognostic relevance of immunoglobulin heavy chain rearrangement and immunoglobulin kappa light chain rearrangement in patients with diffuse large B cell lymphoma.The oncologist · 2025Article
- Advances in biology, diagnosis and treatment of DLBCL.Annals of hematology · 2024Review
- Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas.Cancers · 2024Review
- Tissue-Matched IgH Gene Rearrangement of Circulating Tumor DNA Shows Significant Value in Predicting the Progression of Diffuse Large B Cell Lymphoma.The oncologist · 2024Article
- Measurable Residual Disease Monitoring in Lymphoma.Current hematologic malignancy reports · 2023Review
- Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical).Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Positron Emission Tomography Molecular Imaging for Phenotyping and Management of Lymphoma.Phenomics (Cham, Switzerland) · 2022Review
- Evolution of therapy for limited stage diffuse large B-cell lymphoma.Blood cancer journal · 2022Review
- The role of surveillance computed tomography in patients with follicular lymphoma.Therapeutic advances in hematology · 2022Article
- Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Review
- Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma.The Korean journal of internal medicine · 2021Article
- Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study.International journal of hematology · 2020Article
- The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma.Current oncology reports · 2019Review
- Review
- Surveillance Scans in Lymphoma: Friend or Foe?Current treatment options in oncology · 2017Review
- Follow-up care for survivors of lymphoma who have received curative-intent treatment.Current oncology (Toronto, Ont.) · 2016Review
- Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.Current treatment options in oncology · 2016Review
- Review
- PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma.Current treatment options in oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe usefulness of positron emission tomography with computed tomography (PET-CT) in the surveillance of patients with diffuse large B-cell lymphoma (DLBCL) in complete metabolic remission after primary therapy is not well studied.
methodsWe performed a retrospective review of our database between 2002 and 2009 for patients with de novo DLBCL who underwent surveillance PET-CT after achieving complete metabolic response (CMR) following primary therapy.
resultsFour-hundred and fifty scans were performed in 116 patients, with a median follow-up of 53 (range 8-133) months from completion of therapy. Thirteen patients (11%) relapsed: seven were suspected clinically and six were subclinical (all within first 18 months). The positive predictive value in patients with international prognostic index (IPI) <3 was 56% compared with 80% in patients with IPI ≥3. Including indeterminate scans, PET-CT retained high sensitivity 95% and specificity 97% for relapse.
conclusionPositron emission tomography with computed tomography is not useful in patients for the majority of patients with diffuse large B-cell lymphoma in CMR after primary therapy, with the possible exception of patients with baseline IPI ≥3 in the 18 months following completion of primary therapy. This issue could be addressed by a prospective clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.